Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Chinese and Indian Markets Expand, Young American Drug Outfits Should Hold Onto Ex-U.S. Rights, Says Genzyme Leader

This article was originally published in PharmAsia News

Executive Summary

BOSTON - Despite conventional wisdom and Wall Street's old-fashioned point of view, young American companies starting out should think long and hard before giving up ex-U.S. rights to their discoveries, the top executives of Massachusetts biotechs Genzyme and Biogen Idec advise

You may also be interested in...

Genzyme's Manufacturing Problems Lead To Enforcement Action By FDA

FDA tells Genzyme a consent decree to ensure GMP compliance is likely, but firm notes sanctions would be related only to Allston Landing facility.

Agreement Averts Another Proxy Fight Between Biogen Idec, Icahn

Despite agreeing to support Biogen's nominee slate, Icahn says he still will push for biotech sale.

Varied Outcomes Predicted On Icahn's Bid For Four Seats On Genzyme's Board

Activist investor Carl Icahn seeking the kind of gains similar to those he realized at Biogen Idec.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts